Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.
1. A method for treating a brain cancer that is a glioma, comprising administering a therapeutically effective amount of at least one compound to a subject in need of treatment for a glioma, wherein the compound is selected from the group consisting of:
(a) a Hematopoietic Signal peptide-containing Secreted 1 (HSS1) peptide comprising SEQ ID NO:6;
(b) a Hematopoietic Signal peptide-containing Membrane domain-containing 1 (HSM1) peptide comprising SEQ ID NO:4;
(c) a peptide having at least about 90% homology to a HSS1 peptide comprising SEQ ID NO:6 and comprises amino acids 1-227 of SEQ ID NO: 6, wherein the peptide is capable of reducing proliferation of glioma cells;
(d) any combination thereof.
2. The method of claim 1 , wherein the glioma is glioblastoma multiforme.
3. The method of claim 1 , wherein the glioma is a primary glioma.
4. The method of claim 1 , wherein the compound is delivered via intracerebroventricular infusion.
5. The method of claim 1 , wherein the compound is delivered before or after radiation therapy.
6. The method of claim 1 , wherein the compound is delivered before or after brain surgery to remove all or part of the cancerous tissue.
7. The method of claim 1 , wherein the compound is delivered before or after chemotherapy.
8. The method of claim 1 , wherein the subject treated with the compound has increased survival following treatment.
9. The method of claim 1 , wherein treatment with the compound results in a reduction in tumor mass.
10. The method of claim 1 , wherein (c) is a peptide having at least about 95% homology to a HSS1 peptide comprising SEQ ID NO:6 and comprises amino acids 1-227 of SEQ ID NO: 6, wherein the peptide is capable of reducing proliferation of glioma cells.